Table 2. Second primary malignancies preceding or following the soft-tissue sarcoma diagnosis.
| Tumour type | Number observed before STS | Number observed after STS | Number expected after STS | SMR | 95% CI |
|---|---|---|---|---|---|
| All malignant tumoursa | 90 | 113 | 90.2 | 1.3 * | 1.0–1.5 |
| Prostate cancer | 10 | 18 | 15.3 | 1.2 | 0.7–1.9 |
| Colorectal cancer | 5 | 16 | 12.6 | 1.3 | 0.7–2.1 |
| Urinary tract | 6 | 9 | 5.5 | 1.7 | 0.8–3.1 |
| Lung cancer | 1 | 9 | 6.4 | 1.4 | 0.7–2.7 |
| Soft tissue | 0 | 9 | 0.5 | 17.6 ** | 8.1–33.5 |
| Breast cancer | 19 | 8 | 8.6 | 0.9 | 0.4–1.8 |
| Endometrial cancer | 6 | 5 | 1.8 | 2.8 | 0.9–6.4 |
| Gastric cancer | 1 | 5 | 3.6 | 1.4 | 0.5–3.2 |
| Non-Hodgkin's lymphoma | 5 | 4 | 2.7 | 1.5 | 0.4–3.8 |
| Skin cancer | 8 | 4 | 6.7 | 0.6 | 0.2–1.5 |
| Pancreatic cancer | 0 | 4 | 2.2 | 1.8 | 0.5–4.6 |
| Renal cell cancer | 1 | 3 | 2.2 | 1.4 | 0.3–4.0 |
| Malignant melanoma | 10 | 2 | 2.5 | 0.8 | 0.1–2.9 |
| Hepatobiliary cancer | 0 | 3 | 2.0 | 1.5 | 0.3–4.3 |
| Chronic lymphocytic leukaemia | 2 | 2 | 0.9 | 2.3 | 0.3–8.3 |
| Brain tumour | 0 | 1 | 1.9 | 0.5 | 0.01–2.9 |
| Thyroid gland | 3 | 0 | 0.4 | 0.0 | 0.0–8.6 |
| Ovarian cancer | 3 | 1 | 1.5 | 0.7 | 0.02–3.8 |
CI=confidence interval; SMR=standardised morbidity ratio; STS=soft-tissue sarcoma.
a
In addition to the tumours listed below, 10 additional malignancies, for example, head and neck cancer, developed.
*
P=0.02.
**
P<0.001.